Human/Monkey ESM1 enzyme-linked immunoassay kit

CAT: EH0327 Datasheet
Specification 96 Test
Sensitivity 0.25 pg/ml (50 μl);1.32 pg/ml (10 μl);
Standard Curve Range 46.88 ~3000 pg/ml
Standard Curve Gradient 7 Points
Number of Incubations 2
Detectable sample Liquid phase sample of soluble substances. For example: serum, plasma, cell culture supernatant, tissue grinding liquid, etc.
Sample Volume 50 μl/10 μl
Type Fully Ready-to-Use
Operation Duration 120min
pg/ml O.D. Average Corrected
0.00 0.0071 0.0075 0.0073
46.88 0.0949 0.0941 0.0945 0.0872
93.75 0.1887 0.1830 0.1859 0.1786
187.50 0.3645 0.3432 0.3539 0.3466
375.00 0.7057 0.6816 0.6937 0.6864
750.00 1.2880 1.2520 1.2700 1.2627
1500.00 2.2350 2.2110 2.2230 2.2157
3000.00 3.3820 3.3460 3.3640 3.3567

Precision

Intra-assay Precision Inter-assay Precision
Sample Number S1 S2 S3 S1 S2 S3
22 22 22 6 6 6
Average(pg/ml) 65.7 318.6 935.4 66.5 316.4 965.6
Standard Deviation 2.2 15.0 42.1 1.1 6.7 32.1
Coefficient of Variation(%) 3.3 4.7 4.5 1.7 2.1 3.3

Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty-two times on one plate to assess intra-assay precision. Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.

Spike Recovery

The spike recovery was evaluated by spiking 3 levels of human/monkey ESM1 into health human/monkey serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 85% to 120% with an overall mean recovery of 101%.

Sample Values

Sample Matrix Sample Evaluated Range (pg/ml) Detectable (%) Mean of Detectable (pg/ml)
Human Serum30275.37-526.45100.0408.94
Monkey Serum21729.33-1900.51100.01814.92

Serum/Plasma – Thirty samples from apparently healthy volunteers and two samples from healthy monkeys were evaluated for the presence of human/monkey ESM1 in this assay. No medical histories were available for the donors. n.d. = non-detectable. Samples measured below the sensitivity are considered to be non-detectable.

Background: ESM1

Endocan (endothelial cell proteoglycan; also known as endothelial-cell specific molecule-1 [ESM-1]), is a 50 kDa, monomeric, secreted, cysteine-rich proteoglycan identified initially in endothelial cells of the kidney and lung. Mouse Endocan is synthesized as a 184 amino acid (aa) precursor that contains a 21 aa signal sequence and a 20 kDa, 163 aa mature region. The N-terminal 2/3 of the molecule contains 18 cysteine residues and there are no potential N-linked glycosylation sites. Based on human Endocan, there are at least two potential O-linked glycosylation sites, one of which will likely be utilized on Ser at position # 136 of the mature molecule. The posttranslational modification is approximately 30 kDa in size. It consists of a single dermatan sulfate chain that contains 4-O sulfated N-acetyl galactosamine with alpha -iduronate. This chain is suggested to bind HGF and contribute to HGF mitogenic activity. Mature mouse Endocan is 96% and 74% aa identical to rat and human Endocan, respectively. In human, there is a potential for an alternate splice variant. It shows a deletion of aa’s 82 through 131, a range which would not remove the dermatan sulfate attachment site. It is not known if such a splice form exists in mouse. Endocan is expressed by endothelial cells, adipocytes, bronchial epithelium and distal renal tubular epithelium. It is upregulated by TNF-alpha and VEGF,and is known to bind to LFA-1 ( alpha L beta 2) on the surface of PBMCs, blocking LFA-1 interaction with ICAM-1. Normal circulating levels of Endocan are approximately 1 ng/mL.

Under construction!

Under construction!

Under construction!

Contact Information
Related Products
相关途径
Guarantee